Definium Therapeutics is trading at $41.07 (+5.61%) ahead of its September 14, 2026 webcast discussing topline results from the Phase 3 Panorama study in generalized anxiety disorder.
- The webcast is scheduled for 8:00 a.m. EDT, making the clinical update the clearest pre-market catalyst.
- No trading-volume information was provided; broader market futures were lower, so the move appears company-specific.